DTC
CLYM

Deep Track Capital’s Climb Bio CLYM Stock Holding History

Deep Track Capital’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-509,789
Closed -$1.02M – 73
2025
Q3 		$1.02M Sell
509,789
-530,326
-51% -$985K 0.03% 56
2025
Q2 		$1.29M Hold
1,040,115
– – 0.04% 63
2025
Q1 		$1.27M Hold
1,040,115
– – 0.04% 69
2024
Q4 		$1.87M Sell
1,040,115
-1,129,028
-52% -$4.09M 0.07% 61
2024
Q3 		$11M Sell
2,169,143
-1,735,642
-44% -$12.3M 0.35% 56
2024
Q2 		$27.8M Buy
+3,904,785
New +$26M 0.83% 37

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deep Track Capital's CLYM Position: Q4 2025 in Review

Deep Track Capital sold out of Climb Bio (CLYM) in Q4 2025, closing a stake of 509,789 shares — an estimated $1.02M sold.

Deep Track Capital first reported a position in CLYM in Q2 2024 and held it in 6 quarters. The position peaked at $27.8M in Q2 2024. 65 funds tracked by Wall St. Rank hold CLYM as of Q4 2025.

  • Deep Track Capital reported no remaining Climb Bio position as of Q4 2025 after selling out during the quarter.
  • Deep Track Capital sold 509,789 Climb Bio shares in Q4 2025, an estimated $1.02M.
  • Deep Track Capital first reported a position in Climb Bio in Q2 2024 and held it in 6 quarters.
  • Deep Track Capital's Climb Bio position peaked at $27.8M in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Climb Bio as of Q4 2025.

Based on Deep Track Capital's 13F filing for Q4 2025, filed 13 Feb 2026.